Atropine Treatment For Myopia Is Obvious, Petitioner Tells Board
ALEXANDRIA, Va. — In a Jan. 7 petition for inter partes review filed with the Patent Trial and Appeal Board, a clinical stage ophthalmic company seeks cancellation of various claims of...To view the full article, register now.
Already a subscriber? Click here to view full article